Argos Says FDA Willing To ADAPT To Longer Follow-Up For Immunotherapy
Argos Therapeutics reports FDA support for its plan to continue its ADAPT trial of rocapuldencel-T for metastatic renal cell carcinoma despite a futility finding by the independent data monitoring committee.
You may also be interested in...
The biotech suggests that ADAPT trial design was not ideally structured to show the longer-term benefit that might result from its autologous immunotherapy. Argos plans to discuss its plan with FDA in May, despite analyst skepticism.
New US FDA commissioners have a lot of housekeeping to do before they can get to the fun stuff, according to former associate commissioner Wayne Pines.
US agency's study found that mentioning fewer risks in direct-to-consumer ads helped with recall and in some cases with recognition but led viewers to say they didn’t have enough information.